SiBionics and PharmaSens present integrated continuous sensing and automated insulin delivery vision at EASD 2026
Executive summary: SiBionics and PharmaSens presented their 'See More, Act Earlier' program at the EASD 2026 conference in Milan, focusing on the integration of continuous monitoring with automated insulin delivery. The integration of sensing and delivery is a critical step toward fully automated diabetes management, potentially reducing the burden of manual intervention for patients.
Who is involved: SiBionics, PharmaSens, and the European Association for the Study of Diabetes (EASD).
Likely next: Further clinical validation of integrated devices and potential regulatory filings for combined sensing-delivery systems.
At the European Association for the Study of Diabetes (EASD) 2026 meeting, SiBionics and PharmaSens outlined a vision that links continuous glucose monitoring with automated insulin delivery to create a more seamless closed‑loop system for people with diabetes. The companies described how real‑time sensor data would feed into dosing algorithms designed to adjust insulin delivery proactively, aiming to reduce the manual burden on patients and improve glycemic control. Such an integrated approach mirrors a broader industry shift toward automated diabetes management technologies that seek to combine sensing and therapy in a single platform. By closing the loop between measurement and intervention, the concept could lower the risk of hypo‑ and hyperglycemia, potentially decreasing long‑term complications and the associated costs for healthcare systems. Payers and providers may begin to evaluate these solutions for reimbursement pathways, while competitors are likely to accelerate their own closed‑loop initiatives to keep pace. In the near term, SiBionics and PharmaSens are expected to pursue further clinical validation of the integrated concept, seek regulatory clearance in key markets, and explore pilot collaborations with diabetes clinics or device manufacturers. The broader market will watch for data on safety, usability and real‑world performance, which will shape adoption timelines and influence how quickly similar closed‑loop offerings emerge from other players.
What's next — scenarios
Base: Integrated technology enters clinical trial phase (60%)
Increased R&D expenditure for SiBionics and PharmaSens as they move toward clinical validation.
- Announcement of specific clinical trial protocols
- Partnerships with major insulin pump manufacturers
Upside: Rapid regulatory approval for closed-loop systems (25%)
Significant market share capture in the diabetes MedTech sector.
- Positive Phase II/III data for integrated systems
- FDA or EMA expedited pathway designations
Downside: Integration technical failures (15%)
Delayed product launches and loss of investor confidence in automated delivery reliability.
- Data latency issues in real-time sensing
- Hardware compatibility failures between sensor and pump
What to watch
- Upcoming clinical data presentations at future EASD or ADA meetings
- Regulatory updates from EMA/FDA regarding automated closed-loop devices
- Strategic partnerships between sensing companies and pharmaceutical insulin providers
Timeline
- — SIBIONICS and PharmaSens explore new horizons for automated insulin delivery at EASD 2026 (PR Newswire)
- — Hansoh Pharma presents Phase III data for Olatorepatide at EASD (PR Newswire)
Analysis — what this means
Likely next events
- EASD 2026 conference conclusion (early October 2026)
- Potential release of clinical data for integrated systems in 2027
Sectors affected
- Diabetes MedTech
- Continuous Glucose Monitoring (CGM) manufacturers
- Insulin pump manufacturers
- Pharmaceutical companies specializing in diabetes care
Regulatory implications
- Increased scrutiny on the software algorithms used for automated insulin dosing
- Requirement for high-reliability cybersecurity standards for connected medical devices
Historical parallels
- The transition from manual insulin injections to early CGM systems (2000s)
- The introduction of the first commercial closed-loop 'artificial pancreas' systems
Key entities
Sources
- SIBIONICS and PharmaSens explore new horizons for automated insulin delivery at EASD 2026 — PR Newswire
- Hansoh Pharma presents Phase III data for Olatorepatide at EASD — PR Newswire
Related cases
- SiBionics and PharmaSens showcase integrated continuous sensing and automated insulin delivery concepts at EASD 2026
- SiBionics and PharmaSens showcase a joint vision for automated insulin delivery at EASD 2026, signaling advancing collaboration in diabetes tech
- Sibionics and PharmaSens announce exploration of integrating continuous glucose sensing with automated insulin delivery at EASD 2026
- Hansoh Pharma’s dual‑biased GLP‑1/GIP agonist olatorepatide achieves 19.3% weight loss at week 48, signalling a new contender in the obesity drug market
- Sinocare launches integrated chronic disease management solutions at EASD 2026, signaling expansion in digital health for diabetes care
- Eli Lilly accelerates cardiometabolic leadership with pivotal new clinical data presentation at EASD 2026